Aveanna Healthcare (NASDAQ:AVAH) Insider Sells $138,262.05 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 17,613 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.85, for a total transaction of $138,262.05. Following the transaction, the insider directly owned 1,321,114 shares of the company’s stock, valued at $10,370,744.90. The trade was a 1.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Aveanna Healthcare Stock Down 1.1%

Shares of AVAH stock opened at $8.08 on Monday. The company’s fifty day simple moving average is $8.92 and its two-hundred day simple moving average is $7.52. Aveanna Healthcare Holdings Inc. has a 52 week low of $3.67 and a 52 week high of $10.32. The stock has a market cap of $1.69 billion, a P/E ratio of 22.44 and a beta of 2.06. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39.

Aveanna Healthcare (NASDAQ:AVAH) last issued its earnings results on Monday, May 22nd. The company reported $0.04 earnings per share (EPS) for the quarter. Aveanna Healthcare had a negative return on equity of 143.55% and a net margin of 3.29%.The firm had revenue of $450.53 million for the quarter. Analysts predict that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current fiscal year.

Institutional Trading of Aveanna Healthcare

Several institutional investors have recently added to or reduced their stakes in AVAH. JPMorgan Chase & Co. grew its stake in shares of Aveanna Healthcare by 32.4% during the third quarter. JPMorgan Chase & Co. now owns 209,491 shares of the company’s stock valued at $1,858,000 after buying an additional 51,226 shares during the last quarter. Caxton Associates LLP bought a new stake in shares of Aveanna Healthcare during the 3rd quarter worth approximately $488,000. PharVision Advisers LLC boosted its holdings in Aveanna Healthcare by 37.6% during the 3rd quarter. PharVision Advisers LLC now owns 20,595 shares of the company’s stock valued at $183,000 after acquiring an additional 5,630 shares during the period. XTX Topco Ltd bought a new position in Aveanna Healthcare in the 3rd quarter valued at $531,000. Finally, Voleon Capital Management LP purchased a new stake in Aveanna Healthcare in the third quarter worth $2,949,000. Institutional investors own 87.96% of the company’s stock.

Analysts Set New Price Targets

AVAH has been the subject of a number of recent research reports. William Blair initiated coverage on shares of Aveanna Healthcare in a report on Monday, December 8th. They issued an “outperform” rating for the company. UBS Group lifted their price objective on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 20th. JPMorgan Chase & Co. raised shares of Aveanna Healthcare from an “underweight” rating to a “neutral” rating and increased their price target for the company from $6.00 to $10.00 in a report on Thursday, September 18th. Finally, Truist Financial boosted their price objective on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research note on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.69.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.